Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients

Conditions:   Carcinoma, Basal Cell;   Carcinoma, Cutaneous Squamous Cell Intervention:   Drug: L19IL2 +L19TNF Sponsor:   Philogen S.p.A. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials